ZA202005023B - L2a5 antibody or functional fragment thereof against tumour antigens - Google Patents

L2a5 antibody or functional fragment thereof against tumour antigens

Info

Publication number
ZA202005023B
ZA202005023B ZA2020/05023A ZA202005023A ZA202005023B ZA 202005023 B ZA202005023 B ZA 202005023B ZA 2020/05023 A ZA2020/05023 A ZA 2020/05023A ZA 202005023 A ZA202005023 A ZA 202005023A ZA 202005023 B ZA202005023 B ZA 202005023B
Authority
ZA
South Africa
Prior art keywords
antibody
functional fragment
tumour antigens
against tumour
antigens
Prior art date
Application number
ZA2020/05023A
Other languages
English (en)
Inventor
Paula Alexandra Quintela Videira
Carlos Manuel Mendes Novo
Liliana Raquel Rodrigues Loureiro
Mylène Adelaide Do Rosário Carrascal
José Alexandre Ribeiro De Castro Ferreíra
María Angelina De Sá Palma
Lúcio Lara Santos
Luís Carlos Oliveira Lima
Wengang Chai
Michael Bachmann
Original Assignee
Univ Nova De Lisboa
Inst Portugues De Oncologia Do Porto Fg Epe
Helmholtz Zentrum Dresden Rossendorf Institute Of Radiopharmaceutical Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Nova De Lisboa, Inst Portugues De Oncologia Do Porto Fg Epe, Helmholtz Zentrum Dresden Rossendorf Institute Of Radiopharmaceutical Cancer Res filed Critical Univ Nova De Lisboa
Publication of ZA202005023B publication Critical patent/ZA202005023B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5756—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving tumour-associated glycolinkage [TAG]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/91—Cell lines ; Processes using cell lines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
ZA2020/05023A 2018-01-26 2020-08-13 L2a5 antibody or functional fragment thereof against tumour antigens ZA202005023B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PT110526A PT110526B (pt) 2018-01-26 2018-01-26 Anticorpo, fragmento funcional ou sonda do mesmo contra antigénios tumorais
PCT/PT2019/000001 WO2019147152A1 (en) 2018-01-26 2019-01-17 L2a5 antibody or functional fragment thereof against tumour antigens

Publications (1)

Publication Number Publication Date
ZA202005023B true ZA202005023B (en) 2022-01-26

Family

ID=65244573

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2020/05023A ZA202005023B (en) 2018-01-26 2020-08-13 L2a5 antibody or functional fragment thereof against tumour antigens

Country Status (14)

Country Link
US (1) US11353460B2 (https=)
EP (1) EP3743726B1 (https=)
JP (1) JP7324777B2 (https=)
CN (1) CN113287018B (https=)
AU (1) AU2019211035B2 (https=)
BR (1) BR112020014931A2 (https=)
CA (1) CA3089300A1 (https=)
EA (1) EA202091760A1 (https=)
IL (1) IL276208B1 (https=)
MX (1) MX2020007828A (https=)
PT (1) PT110526B (https=)
SG (1) SG11202006897VA (https=)
WO (1) WO2019147152A1 (https=)
ZA (1) ZA202005023B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4310100A4 (en) * 2021-03-18 2025-05-14 Hirosaki University MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO A SUGAR CHAIN IN WHICH A TERMINAL SIALIC ACID RESIDUE IS BOUND TO GALACTOSE WITH A α2,6 LINKAGE AND METHOD FOR MEASURING THE SUGAR CHAIN WITH A TERMINAL SIALIC ACID RESIDUE BOUND TO GALACTOSE WITH A α2,6 LINKAGE
US20240197882A1 (en) * 2021-04-20 2024-06-20 Ramot At Tel-Aviv University Ltd. Humanized anti-sialyl-tn glycan antibodies and uses thereof
GB2619976A (en) 2022-06-24 2023-12-27 Cellmabs S A Humanised antibodies or functional fragments thereof against tumour antigens
CN121219019A (zh) 2023-05-05 2025-12-26 百欧恩泰欧洲股份公司 用于增强靶向癌症相关抗原的采用新型连接子-有效载荷系统的抗体药物偶联物
WO2026057354A1 (en) * 2024-09-10 2026-03-19 Invox Pharma Limited Anti-sialyl-tn antigen-binding proteins

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU584417B2 (en) 1985-04-01 1989-05-25 Lonza Group Ag Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
ATE123066T1 (de) * 1988-03-11 1995-06-15 Biomembrane Inst Monoklonale antikörper und herstellung eines impfstoffes gegen menschliche krebsantigene durch immunisierung mit menschlichem und tierischem mucin und mit synthetischen gluciden- trägerkonjugaten.
CA2189356A1 (en) 1994-05-02 1995-11-09 Ting Chi Wong Process for preparation of glycosides of tumor-associated carbohydrate antigens
EP0996455B1 (en) 1997-04-16 2009-12-16 Sloan-Kettering Institute For Cancer Research Alpha-o-linked glycoconjugates with clustered (2,6)-st epitopes, methods of preparation and uses thereof
CU22731A1 (es) * 1998-02-05 2002-02-28 Centro Inmunologia Molecular Anticuerpo monoclonal que reconoce el oligosacárido ácido siálico n´glicolilado-galactosa-glucosa (ngcneu-gal-glu) en tumores malignos y composiciones farmacéuticas que los contienen
JP3809277B2 (ja) 1998-03-05 2006-08-16 生化学工業株式会社 Ｎ−アセチルグルコサミン−６−ｏ−硫酸基転移酵素のポリペプチド及びそれをコードするｄｎａ
GB9917012D0 (en) 1999-07-20 1999-09-22 Pharmacia & Upjohn Spa Combined preparations comprising antitumor agents
EP1651955A4 (en) 2003-07-15 2007-11-21 Univ California PROCESS FOR THE DETECTION AND ANALYSIS OF N-GLYCOLYLNEURAMIC ACID (NEU5GC) IN BIOLOGICAL MATERIALS
US8148335B2 (en) 2004-06-23 2012-04-03 Children's Hospital & Research Center Oakland De-N-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy
EP2083868A2 (en) 2006-10-04 2009-08-05 Københavns Universitet Generation of a cancer-specific immune response toward muc1 and cancer specific muc1 antibodies
JP5156887B2 (ja) * 2007-02-14 2013-03-06 独立行政法人科学技術振興機構 ２−６シアリル６−スルホ糖鎖に対する抗体
EP2014302A1 (en) 2007-07-12 2009-01-14 Institut Curie An antibody specific for the Tn antigen for the treatment of cancer
FI20070853A0 (fi) * 2007-11-09 2007-11-09 Glykos Finland Oy Glykaania sitovat monoklonaaliset vasta-aineet
EP2287202A1 (en) 2009-08-07 2011-02-23 Dublin City University Anti-sialic acid antibody molecules
EP2524233A4 (en) 2010-01-15 2013-07-31 Univ California COMPOSITIONS AND METHOD FOR DETECTING CANCER
JP6172687B2 (ja) 2013-05-02 2017-08-02 国立研究開発法人産業技術総合研究所 シアリル化糖鎖を認識するモノクローナル抗体
WO2014191128A1 (en) 2013-05-29 2014-12-04 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
KR102313341B1 (ko) 2013-08-26 2021-10-18 바이오엔테크 리서치 앤드 디벨롭먼트 인코포레이티드 시알릴-루이스 ａ에 대한 사람 항체 코드화 핵산
EP2990416B1 (en) 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
US20180280504A1 (en) * 2014-10-10 2018-10-04 Siamab Therapeutics, Inc. Glycan-interacting compounds and methods of use
US11279769B2 (en) * 2015-08-31 2022-03-22 Helixmith Co., Ltd Anti-Sialyl Tn chimeric antigen receptors
EP3645703B1 (en) * 2017-05-25 2025-11-26 Instituto de Patologia e Imunologia da Universidade do Porto (IPATIMUP) Detection and isolation of cancer cells from body fluids based on a glycosylation pattern and methods of use thereof

Also Published As

Publication number Publication date
CA3089300A1 (en) 2019-08-01
US20210033616A1 (en) 2021-02-04
CN113287018B (zh) 2025-10-28
EA202091760A1 (ru) 2020-11-23
SG11202006897VA (en) 2020-08-28
US11353460B2 (en) 2022-06-07
EP3743726B1 (en) 2024-06-12
MX2020007828A (es) 2020-11-24
PT110526B (pt) 2021-02-04
PT110526A (pt) 2019-07-26
IL276208B1 (en) 2026-02-01
JP2021516254A (ja) 2021-07-01
CN113287018A (zh) 2021-08-20
BR112020014931A2 (pt) 2020-12-08
AU2019211035B2 (en) 2025-08-14
WO2019147152A1 (en) 2019-08-01
AU2019211035A1 (en) 2020-08-06
IL276208A (en) 2020-09-30
EP3743726A1 (en) 2020-12-02
JP7324777B2 (ja) 2023-08-10
KR20210005546A (ko) 2021-01-14

Similar Documents

Publication Publication Date Title
IL279321A (en) Anti-SIRPalpha antibody
ZA202004494B (en) Anti-tmprss2 antibodies and antigen-binding fragments
IL283812B (en) Humanized antibody against human pd–1
SG11202106214YA (en) Novel anti-ccr8 antibody
IL269593A (en) Anti-ILT4 antibodies and antigen-binding fragments
EP3258967A4 (en) Bivalent antibody directed against nkg2d and tumor associated antigens
ZA201700528B (en) Anti-ctla4 monoclonal antibody or antigen binding fragment thereof, medicinal composition and use
GB201817172D0 (en) Antibody
ZA202005023B (en) L2a5 antibody or functional fragment thereof against tumour antigens
ZA202101177B (en) Anti-btla antibody
ZA201903896B (en) Novel anti-human muc1 antibody fab fragment
GB201811368D0 (en) Antibody
IL291082A (en) Anti-vsig4 antibody or antigen-binding fragment and uses thereof
IL277296A (en) Antibodies against PFRH5 and their antigen-binding fragments
ZA202005419B (en) C-terminal antibody variants
SI3269735T1 (sl) Protitelo proti sklerostinu, antigen-vezavni fragment in medicinska uporaba le-tega
GB201911211D0 (en) Monoclonal antibodies against ambra-1
SG11202007750PA (en) Cancer antigen peptide
GB201911931D0 (en) Anti-C7 antibody or antibody fragment
SG11202105718TA (en) Modified antibodies
DK3743726T3 (da) L2a5-antistof eller funktionelt fragment deraf mod tumorantigener
GB201813597D0 (en) Antibody
GB201809945D0 (en) Antibody